CORAL GABLES, Fla., March 27 /PRNewswire/ -- Stiefel Laboratories, Inc. (SLI), the world's largest independent pharmaceutical company specializing in dermatology, has announced the purchase of a facility in Research Triangle Park, N.C. Stiefel Research Institute, Inc. (SRI), a subsidiary of SLI, will open its global R&D headquarters in the fourth quarter of 2006 and will relocate its current, New York-based U.S. R&D site to the new facility as well. SRI plans to create 200 jobs and invest more than $50 million in the facility over the next five years.
Charles W. Stiefel, chairman of the board, CEO and president of SLI, said the move will be good for his company. "We are very excited that the Stiefel Research Institute is relocating to an area with the R&D prestige of Research Triangle Park," he said. "The relocation of our Research Institute contributes to Stiefel's strategic evolution toward being the most-valued dermatological company in the world."
SLI has its world headquarters in Coral Gables, Fla. and employs approximately 3,000 people worldwide. Stiefel Laboratories specializes in the research, development and manufacture of prescription and over-the-counter skin care products to treat acne, psoriasis, hyperpigmentation and other skin conditions. The SRI facility in Durham County would conduct research and development (R&D) covering a wide range of dermatological conditions in support of the company's worldwide initiatives.
"The SRI facility in Research Triangle will serve as a critical achievement to further strengthen Stiefel's network of R&D infrastructure," said Dr. Marco Taglietti, senior vice president of global R&D, Stiefel Laboratories, Inc. "This world-class facility will host our global R&D headquarters working hand-in-hand with our two international R&D centers of excellence in Maidenhead, England and Bonsucesso-Guarulhos, Brazil to advance the development of new and innovative dermatological drugs and products."
About Stiefel Laboratories, Inc.
Founded in 1847, Stiefel Laboratories is the world's largest independent pharmaceutical company specializing in dermatology. Its wholly owned global network is comprised of more than 30 subsidiaries, including manufacturing plants in six countries, and R&D facilities on three continents. Stiefel supplements its R&D by aggressively seeking acquisitions of dermatological product lines and companies around the world. To learn more about Stiefel, visit http://www.stiefel.com.
Stiefel Laboratories, Inc.CONTACT: Erin Bacher of Ogilvy Public Relations Worldwide,+1-404-881-2324, or erin.bacher@ogilvypr.com, for Stiefel Laboratories,Inc.
Web site: http://www.stiefel.com/
